Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen

Sutro Biopharma (NASDAQ:STRO) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other research firms have also commented on STRO. Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target on the stock in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. Truist Financial raised shares of Sutro Biopharma to a “strong-buy” rating in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Finally, Wedbush reaffirmed a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sutro Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $37.29.

Sutro Biopharma Price Performance

Shares of NASDAQ STRO opened at $24.43 on Friday. Sutro Biopharma has a 1-year low of $5.23 and a 1-year high of $26.54. The company has a market capitalization of $207.90 million, a price-to-earnings ratio of -0.94 and a beta of 1.47. The business has a 50-day moving average of $19.06 and a 200-day moving average of $12.94.

Institutional Trading of Sutro Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Bridgeway Capital Management LLC lifted its holdings in Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after buying an additional 30,000 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares during the last quarter. Cerity Partners LLC increased its holdings in shares of Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Sutro Biopharma during the 2nd quarter valued at approximately $82,000. Finally, State of Tennessee Department of Treasury bought a new position in Sutro Biopharma during the fourth quarter worth $86,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55, signaling strong upside from current levels; that lift to a much higher PT supports bullish investor sentiment. Deutsche Bank Raises Price Target to $55
• Positive Sentiment: Wells Fargo upgraded Sutro to “Overweight,” an endorsement that can attract institutional buying. Wells Fargo Upgrades Sutro Biopharma to Overweight
• Positive Sentiment: Truist moved the stock to “strong-buy” (reported via Zacks), another supportive vote of confidence from the sell side. Truist Upgrades to Strong-Buy (Zacks)
• Neutral Sentiment: HC Wainwright published commentary on Sutro’s FY2030 outlook — the note offers long‑range modeling context but is not a straightforward buy/sell trigger by itself. HC Wainwright Comments on Sutro FY2030 Earnings
• Negative Sentiment: HC Wainwright sharply cut near‑term and multi‑year EPS forecasts (Q1–Q4 FY2026 and FY2026–FY2029), moving projected losses much deeper while keeping a Buy rating and a $28 target. Those sizable downward revisions increase short‑term downside risk and help explain selling pressure despite upgrades. HC Wainwright Lowers Multiple EPS Estimates (MarketBeat)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.